Medicinal cannabis hub
Information about access pathways for medicinal cannabis products.
The medicinal cannabis hub brings together information on the regulation of medicinal cannabis in Australia along with guidance material and information resources for consumers, health professionals, sponsors, and manufacturers.
While the TGA regulates the access, most medicinal cannabis products are considered to be unapproved medicines. Unapproved medicines have not been assessed by the TGA for safety, quality or effectiveness.
However, where clinically appropriate, there are pathways for registered health care professionals to access medicinal cannabis products for their patients.
- Applications and reporting
- Medicinal cannabis products by active ingredients
- Resources, clinical trials and clinical evidence
- Presentation: TGO93 testing and regulation of medicinal cannabis
Frequently asked questions
- Access to medicinal cannabis products
- Accessing medicinal cannabis for a patient
- Importation, manufacture and supply of unapproved medicinal cannabis products
- Medicinal cannabis Special Access Scheme Category A data
- Medicinal cannabis Special Access Scheme Category B data
- Webinar presentation: Medicinal cannabis - Changes to Special Access Scheme (SAS) and Authorised Prescriber applications, 22 November 2021
- Webinar presentation: Medicinal cannabis - Changes to sponsor requirements for supplying unapproved medicinal cannabis products in Australia, 22 November 2021
- Webinar presentation: Medicinal cannabis - Changes to Special Access Scheme (SAS) and Authorised Prescriber applications, 23 November 2021
- Webinar: Medicinal cannabis reforms
- Naturally Elevated Pty Ltd and an individual fined $138,600 for alleged unlawful advertising of medicinal cannabisWe have issued infringement notices to the company Naturally Elevated Pty Ltd and an individual for the alleged unlawful advertising of medicinal cannabis on websites and social media pages.
- The TGA has issued five infringement notices totalling $82,500 were issued to the company, and 3 notices totalling $9,900 were issued to an individual.
- Affinity Corp Australia Pty Ltd fined $66,600 for alleged unlawful advertising of medicinal cannabis productsThe TGA has issued 5 infringement notices to Affinity Corp Australia Pty Ltd for the alleged unlawful advertising of medicinal cannabis products.
- Public notice of the delegate's final decision to amend the Poisons Standard in relation to cannabidiol (private application and delegate initiated) - Joint ACMS-ACCS #25 and #26 (June and November 2020).
- This document reflects the evidence supporting the use of medicinal cannabis in treating chronic pain and the recommendations of the Chronic Pain Working Group